The Germany intrauterine contraceptive (IUC) market is witnessing robust growth due to increasing awareness of long-acting reversible contraceptives, favorable healthcare policies, and rising preference for non-hormonal birth control methods. The market was valued at USD 162 million in 2025 and is expected to reach USD 278 million by 2035, expanding at a CAGR of 5.3% from 2024 to 2035.
The economic impact of tariffs on "Germany Intrauterine Contraceptive".
Market Growth Drivers
Rising Demand for Long-acting Reversible Contraceptives: In Germany, there is a growing demand for long-acting reversible contraceptives (LARCs), such as intrauterine devices (IUDs), due to their high efficacy, convenience, and fewer side effects compared to daily oral contraceptives. According to Bayer AG, one of the leading market players in the country, educational initiatives and awareness campaigns have led to increased adoption, especially among young women and working professionals seeking reliable birth control methods.
Supportive Healthcare Policies and Insurance Coverage: The German government's focus on enhancing reproductive health and family planning has resulted in favorable healthcare policies, including partial or full insurance coverage for IUCs. As reported by Jenapharm GmbH & Co. KG, recent changes in the public health insurance act allow more women of different age groups to access modern contraceptives at reduced costs, driving market uptake.
Market Trends
Introduction of Next-generation Hormonal IUDs: Companies such as Bayer AG have launched next-generation hormonal IUDs like Kyleena and Mirena, which offer lower hormone doses and longer duration of action. The launch of such advanced products is an emerging trend, providing enhanced safety profiles and catering to the increased demand for low-maintenance birth control.
Growing Focus on Non-Hormonal Copper IUDs: There has been a noticeable increase in interest towards non-hormonal copper IUDs among German women, especially those with contraindications to hormonal methods. Eurogine S.L. has introduced innovative copper IUD variants, responding to a segment of users seeking hormone-free options, aligning with the natural contraception movement in Germany.
Market Opportunities
Expanding Telemedicine for Contraception Counseling: Companies like HelloBetter and telemedicine platforms are increasingly providing digital contraception counseling and prescription services, making IUC insertion and management more accessible to remote populations, driving future market growth.
Product Innovation for Adolescent and Nulliparous Women: Market players are focusing on developing smaller, flexible IUDs suitable for adolescents and women who have not given birth. This broadened product availability can significantly capture untapped segments.
From 2020 to 2025, Germany’s intrauterine contraceptive market demonstrated steady growth, increasing from USD 120 million to USD 162 million, reflecting growing awareness and adoption. The forecast anticipates a robust expansion, reaching roughly USD 278 million by 2035, propelled by continued product innovation, supportive policies, and broader insurance coverage. The chart showcases a consistent upward trajectory, with notable inflection points expected between 2027-2030 as product launches and digital health initiatives accelerate market penetration.
Germany Intrauterine Contraceptive Market by Region Share (%), 2025
In 2025, Southern Germany leads with 34% of the country’s intrauterine contraceptive market, driven by advanced healthcare infrastructure and higher consumer awareness. Western Germany holds 28% market share, supported by robust public health initiatives. Eastern and Northern Germany account for 18% and 15%, respectively, reflecting slower uptake due to regional disparities in access and awareness. Central Germany captures a smaller but growing segment with 5% share, following an increase in urban healthcare investments.
Recent Developments
In March 2024, Bayer AG announced the successful rollout of an updated Mirena IUD with a new inserter design, aiming to improve comfort and ease of insertion for healthcare providers and patients across major German metropolitan areas.
In April 2024, Jenapharm GmbH & Co. KG reported strategic expansion of partnership with public health insurance providers, further streamlining coverage and reimbursement for its hormone-releasing IUDs, leading to an uptick in product adoption among younger women.
In May 2024, Eurogine S.L. introduced its next-generation frameless copper IUD in select German clinics, addressing unmet demand among users seeking hormone-free options and supporting the ongoing trend towards personalized contraception solutions.
Press Releases